Clinical Trials


FREE Study: Efficacy and Toxicity of Trizivir

This study has been completed
Rijnstate Hospital


Information provided by (Responsible Party)
Rijnstate Hospital Identifier

First received: November 29, 2006
Last updated: May 31, 2010
Last Verified: May 2010
History of Changes


Antiretroviral naïve patients with <350 xE6/l CD4 cells and a HIV-viral load of > 30.000 cop/ml are started on combivir ® and Kaletra ®. When patients have reached an undetectable viral load of< 50 cop/ml on two consecutive occasions at least at week 12, but no later than week 24, they are randomised in either continuation with Combivir/Kaletra or switch to Trizivir ® twice daily one pill during 96 weeks. All patients randomised in the combivir/Kaletra arm are eligible to switch to Trizivir at any post randomisation visit when they reach predefined switch criteria for elevated levels of fasting glucose or lipids.

Condition Intervention Phase
HIV Infections

Drug : Trizivir
Drug : zidovudine,lamivudine,abacavir
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Free Study: a Randomised, Open Label, Multicentre Strategic Study to Evaluate the Efficacy and Toxicity of an Early Switch From a PI-containing Regimen to Trizivir ® on Guidance of Viral Load in HIV-1 Infected , Antiretroviral naïve Adults

Further study details as provided by Rijnstate Hospital:

Primary Outcome Measures

  • Plasma HIV-RNA < 400 cop/ml at week 96 for the Intent- To-Treat (ITT).
Secondary Outcome Measures:
  • HIV-RNA <50 cop at week 96
  • HIV-RNA <400 and <50 cop/ml at week 48
  • Time to virological failure
  • Immunological efficacy at week 48 and 96 measured by absolute change from baseline in CD4 cell counts
  • Duration of change in CD4 cell count from baseline to >200,
  • Proportion of subjects experiencing one or more predefined values of fasting glucose and triglycerides, LDL and LDL/HDL ratio
  • Development of adverse events

Enrollment: 207
Study Start Date: March 2003
Study Completion Date: September 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: combivir/kaletra
All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
Drug: zidovudine,lamivudine,abacavir

zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid

Experimental: Trizivir
patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
Drug: Trizivir

Detailed Description:

The primary objective is to compare the antiviral efficacy of an early switch from a boosted PI/2NRTI regimen to Trizivir (after undetectability of HIV-RNA has been achieved on 2 consecutive occasions) with uninterrupted use of the PI/2NRTI regimen for 96 weeks.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Adults >18 years of age, confirmed HIV-1 infection, never received antiretrovirals before, plasma-HIV-RNA >30.000 cop/ml, CD4 < 350 E6/l.

Exclusion Criteria:
  • pregnancy, women using proven barrier methods of contraception, defined uncontrolled
active AIDS defining complication, being on treatment for diabetes, other serious illnesses, expected non-compliance, defined laboratory abnormalities

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00405925


Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6800 TA

Sponsors and Collaborators

Rijnstate Hospital


Principal Investigator: Clemens Richter, MD Rijnstate Hospital, Arnhem, the Netherlands
Study Director: P. Mulder Rijnstate Hospital, Arnhem, the Netherlands
Study Director: N. Langebeek Rijnstate Hospital, Arnhem, the Netherlands
Study Director: D. N. Burger Nijmegen, the Netherlands
Study Director: P. P. Koopmans Nijmegen, the Netherlands
Study Director: C. H. ten Napel Enschede, the Netherlands
Study Director: P. H. Groeneveld Isala kliniek, Zwolle, the Netherlands
Study Director: H. G. Sprenger Groningen, the Netherlands
Study Director: R. W. ten Kate Haarlem, the Netherlands
Study Director: M. E. van Kasteren Tilburg, the Netherlands
Study Director: J. D. Le grand Charleroi, Belgium
Study Director: R. Vriesendorp The Hague, the Netherlands
Study Director: B. Bravenboer Eindhoven, the Netherlands
Study Director: I. M. Hoepelman Utrecht, the Netherlands
Study Director: P. van Bentum Rijnstate Hospital, Arnhem, the Netherlands
Study Director: A. Smit-den Baars Rijnstate Hospital, Arnhem, the Netherlands
More Information

More Information

Responsible Party: Rijnstate Hospital Identifier: NCT00405925   History of Changes  
Other Study ID Numbers: LTC-184-010403  
Study First Received: November 29, 2006  
Last Updated: May 31, 2010  

Keywords provided by Rijnstate Hospital:

Treatment Naive

Additional relevant MeSH terms:
HIV Infections
Lamivudine, zidovudine drug combination processed this data on July 20, 2018
This information is provided by